Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 2,810 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: matched control group Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Maternal and Child Health Through Point-of-care STI Testing

NCT07290439
View directory record Official record
Conditions
Treponema Pallidum Infection, Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Trichomonas Vaginalis Vaginitis, Sexually Transmitted Infection
Interventions
Point-of-care STI tests, Standard of care STI testing
Diagnostic Test
Lead sponsor
Emory University
Other
Eligibility
Female only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder

NCT01072929
View directory record Official record
Conditions
Depression
Interventions
Armodafinil, Placebo
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 65 Years
Enrollment
433 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
40
States / cities
Birmingham, Alabama • Beverly Hills, California • Garden Grove, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2016 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional Results available

Improving Control and Reducing the Risk of Hypoglycemic Episodes in Type 1 Diabetes

NCT00315939
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1), Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)
Device
Lead sponsor
Boris Kovatchev, PhD
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional

STORIES-Stories to Communicate Risk About Tobacco

NCT00101491
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases
Interventions
Health Communication DVD video
Behavioral
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
19 Years to 78 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Compassion Training and Mindfulness Training for Social Well-Being and Mental Health

NCT05227794
View directory record Official record
Conditions
Anxiety, Depression, Stress, Burnout, Emotion Regulation, Social Acceptance, Loneliness, Compassion
Interventions
Compassion Cultivation Training (CCT), Mindfulness-Based Stress Reduction (MBSR)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
290 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 31, 2026, 9:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer

NCT02032823
View directory record Official record
Conditions
Breast Cancer
Interventions
Olaparib, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
1,837 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
368
States / cities
Anchorage, Alabama • Anchorage, Alaska • Gilbert, Arizona + 321 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Pilot Study to Identify Biomarkers Associated With Chronic Traumatic Brain Injury

NCT01171131
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Blood/saliva sampling
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

NCT06883305
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 80 Years
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
72
States / cities
Foley, Alabama • Mobile, Alabama • Sheffield, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Active, not recruiting Not applicable Interventional

Autonomic Modulation in Takotsubo Syndrome

NCT03324529
View directory record Official record
Conditions
Takotsubo Syndrome
Interventions
Tako Breath
Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

H5N1 Mix and Match With AS03

NCT01317758
View directory record Official record
Conditions
Influenza
Interventions
AS03 Adjuvant, Phosphate Buffered Saline (PBS) diluent, Sanofi H5N1 Antigen
Drug · Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Baltimore, Maryland • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety

NCT03689738
View directory record Official record
Conditions
Insulin Sensitivity, Lipid Metabolism, Resistant Starch, Potato
Interventions
Potato (Resistant Starch), CHO-matched (Low-fiber, RS-free)
Other
Lead sponsor
Midwest Center for Metabolic and Cardiovascular Research
Other
Eligibility
18 Years to 74 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep

NCT03679884
View directory record Official record
Conditions
Insomnia Disorder
Interventions
Daridorexant 10 mg, Daridorexant 25 mg, Daridorexant 50 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
53
States / cities
Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 31, 2026, 9:38 PM EDT
Active, not recruiting Phase 3 Interventional

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI)
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
672 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
35
States / cities
Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder

NCT04041284
View directory record Official record
Conditions
Migraine, Major Depressive Disorder
Interventions
Fremanezumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
17
States / cities
Little Rock, Arkansas • San Diego, California • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2023 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 2 Interventional

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

NCT04857112
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Game Plan for PrEP

NCT04973267
View directory record Official record
Conditions
Human Immunodeficiency Virus Exposure, Alcohol; Harmful Use
Interventions
Game Plan for PrEP, Attention-Matched Control Lifestyle Habits Videos
Behavioral
Lead sponsor
Brown University
Other
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 31, 2026, 9:38 PM EDT
Completed No phase listed Observational

Hypertension Management Using Remote Patient Monitoring

NCT05562921
View directory record Official record
Conditions
Hypertension
Interventions
Controls-ususal care, Cases-remote patient monitoring prescribed
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 110 Years
Enrollment
1,440 participants
Timeline
2018 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 5, 2024 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nitazoxanide Pharmacokinetic Parameters in Renal Impaired Subjects

NCT05368935
View directory record Official record
Conditions
Renal Impairment, Renal Disease, Kidney Disease
Interventions
Nitazoxanide
Drug
Lead sponsor
Genfit
Industry
Eligibility
18 Years to 80 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 31, 2026, 9:38 PM EDT
Not listed Not applicable Interventional

Adherence Intervention for HIV-infected Drug Users

NCT02907697
View directory record Official record
Conditions
HIV, Substance Use
Interventions
Life Steps-Drug Use, General Health Education
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional

Effect of Bacillus Coagulans and Galactomannans on Obese Patients Undergoing Sleeve Gastrectomy

NCT02868489
View directory record Official record
Conditions
Obesity, Quality of Life
Interventions
LactoWise®, Placebo
Dietary Supplement · Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 31, 2026, 9:38 PM EDT
Active, not recruiting Phase 2 Interventional

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

NCT07277660
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Galvokimig, Placebo
Biological · Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
19
States / cities
Oceanside, California • Santa Monica, California • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of New Zealand Blackcurrant Supplementation on Exercise and Cognitive Performance in Resistance-Trained Adults

NCT07619976
View directory record Official record
Conditions
Resistance Exercise Performance, Cognitive Function, Anaerobic Performance, Dietary Supplementation Athletic Performance
Interventions
Low-dose Blackcurrant Supplement, High-dose Blackcurrant Supplement, Maltodextrin (Placebo)
Dietary Supplement
Lead sponsor
Jacksonville State University
Other
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Jacksonville, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Recruiting Phase 3 Interventional

A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

NCT04965675
View directory record Official record
Conditions
Chronic Migraine in Children
Interventions
Eptinezumab, Placebo
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
12 Years to 17 Years
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
22
States / cities
New Haven, Connecticut • Stamford, Connecticut • Washington D.C., District of Columbia + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 31, 2026, 9:38 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients

NCT03127267
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Masitinib (6.0), Riluzole, Placebo, Masitinib (4.5)
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years to 81 Years
Enrollment
495 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • Lexington, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 31, 2026, 9:38 PM EDT